Lung cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• EGFR 301
• PD-L1 162
• PD-1 157
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 65+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

  NCT05378763· Spectrum Pharmaceuticals, Inc· Updated 28 Oct 2026

  “The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

  NCT07428044· Memorial Sloan Kettering Cancer Center· Updated 20 Oct 2026

  “sponsor closed study”Registry text, quoted unchanged. Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

• Terminated

  A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  NCT05514717· Day One Biopharmaceuticals, Inc.· Updated 18 Jun 2026

  “Development discontinued.”Registry text, quoted unchanged. Source

• Terminated

  Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

  NCT03066206· M.D. Anderson Cancer Center· Updated 20 Feb 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Terminated

  A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

  NCT04982926· Taiho Oncology, Inc.· Updated 14 Oct 2025

  “After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

  NCT04278144· Bolt Biotherapeutics, Inc.· Updated 15 Sept 2025

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Terminated

  DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

  NCT03505710· Daiichi Sankyo· Updated 30 May 2025

  “Last participant transitioned to alternative study.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Real-world Outcome of Zongertinib in Japan (J-HERZ)

  NCT07926308· Boehringer Ingelheim· Source

• An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.

  2025-523824-39-01· Medica Scientia Innovation Research S.L.· Source

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Jazz Pharmaceuticals· Source

• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Boehringer Ingelheim· Source

• A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

  NCT03807778· Takeda· Source

• A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

  NCT02716116· Takeda· Source

• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Daiichi Sankyo· Source

• A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

  NCT05048797· AstraZeneca· Source

• A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

  NCT07428044· Memorial Sloan Kettering Cancer Center· Source

• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  NCT06625775· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 313
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 66
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 190
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 616
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 115
• Machine Learning 290
• Deep Learning 210
• Cohort Studies 289
• Genome-Wide Association Study 75

• Comparison of Two Deep Learning Models and Their Combination for 1-year Lung Cancer Detection in Two Screening Cohorts.

  Radiol Cardiothorac Imaging, Dec 2026

• Multimodal Transformer Integrating CT and Pathology for Postoperative Risk Stratification in Stage I Non-Small Cell Lung Cancer.

  Radiol Imaging Cancer, Nov 2026

• Estimating heterogeneous treatment effects with survival outcomes via a deep survival learner.

  Lifetime Data Anal, Oct 2026

• External evaluation of a deep learning-based algorithm for automated lung tumor and esophagus segmentation on CBCT.

  Biomed Phys Eng Express, Oct 2026

• ReViT-RF: A hybrid ResNet-50-Vision Transformer with a Radiomic Feature Fusion framework for lung tumor classification and TNM-based stage prediction using CT images.

  PLoS One, Oct 2026

• EffAtt-LungNet: An attention-guided EfficientNet framework for three-class lung histopathology classification.

  PLoS One, Oct 2026

• Identification of YES1 Inhibitors From Approved Drugs Using a Multimodal Deep Learning Framework.

  Mol Inform, Oct 2026

• A transfer learning-based hybrid deep- and machine-learning regression approach for predicting the postoperative pulmonary function.

  Eur Radiol Exp, Sept 2026

• An end-to-end deep learning approach for lung nodule segmentation and classification using LN-DETR and deep sequential convolutional harmonic networks.

  Comput Biol Med, Sept 2026

• Differential Diagnosis of Lung Cancer Using Artificial Intelligence-Based Extracellular Vesicle Analysis: A Pilot Study.

  ACS Nano, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.